E-Mergir: a digital program to support mental and sexual health for prostate cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial tests a digital, CBT- and mindfulness-based psychosexual intervention for men who have survived prostate cancer. The program, delivered online over eight weeks with five modules, includes psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring, and relapse prevention, guided by a certified clinical psychologist. Participants are randomly assigned to receive the E-Mergir program or be on a wait-list control, with assessments at baseline, post-intervention, and follow-up using validated sexual and mental-health measures. Recruitment occurs through the Urology department at Coimbra University Hospital, and eligibility requires prostate cancer survivorship, 18 years or older, smartphone use, internet access, and no recent other cancers. The study is led by Universidade do Porto and is conducted in Porto, Portugal.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Prostate cancer survivors,
* 18 years old or older,
* Ability to give informed consent,
* Regular use of a smartphone and internet access.

Exclusion Criteria:

* Other diagnosed oncological diseases over the past five years,
* Severe neurological impairment or other severe psychological/psychiatric diseases (depression, generalized anxiety disorder, psychosis-related disorders),
* Other uncontrolled/unstable diseases,
* Severe hearing and/or visual impairment,
* Under psychotherapy or treatment for sexual problems,
* Participating concurrently in other clinical trials.

Where it's running

• Faculdade de Psicologia e de Ciências da Educação da Universidade do Porto
  Porto, Portugal Recruiting

Study contacts

• Study coordinator: Ana Luísa Quinta Gomes, PhD
• Email: bisagomes@gmail.com
• Phone: +351965816335

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.